In the News
January 3, 2023 :
Genetic Engineering and Biotech News: Opus Genetics Acquires Two Gene Therapy Candidates for Inherited Retinal Diseases
Opus acquired the rights to two AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) from Iveric Bio. » Full Story
October 1, 2022 :
Healio: Opus Genetics CEO discusses IND application for retinal degeneration gene therapy
A video interview with Opus CEO Dr. Ben Yerxa on Opus first IND application for LCA5 » Full Story
September 6, 2022 :
PharmaVoice: PharmaVoice 100 Entrepreneurs – Ben Yerxa
A profile of Opus CEO Dr. Ben Yerxa on founding Opus and his career in advancing therapies for ophthalmic conditions. » Full Story
August 1, 2022 :
Life Science Leader: Venture Philanthropy Launches Biotech from Within
An interview with Opus CEO Dr. Ben Yerxa on founding the company and the Opus mission. » Full Story
June 6, 2022 :
Eye on the Cure Podcast: Ash Jayagopal, PhD Interview
Foundation Fighting Blindness Host Ben Shaberman talks with Ash Jayagopal, chief scientific officer at Opus Genetics. » Full Story
December 2, 2021 :
WRAL TechWire: StartUP Spotlight An interview with Opus CEO Dr. Ben Yerxa on Opus’ mission.
Opus Genetics recently announced it would open its third preclinical trial, just a few months after the company formed with a $19 million seed financing round led by the venture capital arm of the Foundation Fighting Blindness, the RD Fund. » Full Story
